Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis

Documenti analoghi

• Renal and multisystem effectiveness of 3.9 years of migalastat in a global real‐world cohort: Results from the followME Fabry Pathfinders registry
  di: Derralynn A. Hughes, et al.
  Pubblicazione: (2024)
• Real‐World Migalastat Use in Fabry Disease: Comparative Insights From the Pisani and Hughes Studies
  di: Eleonora Riccio, et al.
  Pubblicazione: (2025)
• A phase III, open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies
  di: Myrl Holida, et al.
  Pubblicazione: (2024)
• Correction to “Clinical Outcomes in Patients Switching From Agalsidase Beta to Migalastat: A Fabry Registry Analysis”
  Pubblicazione: (2025)
• A Meta‐Analysis to Unveil the Diagnostic Gaps in Anderson–Fabry Disease in Women
  di: L. Lenzini, et al.
  Pubblicazione: (2026)